Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

HSE Warns Businesses Not To Be Misled Over New Law Poster, UK
The Health and Safety Executive (HSE) is warning businesses across Britain not to be duped into buying unnecessary and overpriced copies of its health and safety law poster.
generic viagra online
Evaluating More Lymph Nodes May Not Improve Identification Of Late-Stage Colorectal Cancer
Surgically removing and evaluating an increasing number of lymph nodes does not appear to identify a greater number of patients with stage III colorectal cancer, according to a report in the July issue of Archives of Surgery, one of the JAMA/Archives journals.
News of the day
Economist Examines 'Snail-Fever' In China
The Economist examines schistosomiasis in China. The disease, which is also called snail-fever, is the "world"s second-most prevalent tropical disease after malaria, affecting 207 million people of whom 726,000 are Chinese, according to the most recent official figures, from 2004," the Economist reports.
Health Insurance

Funxional Successfully Completes Initial Clinical Trial Of FX125L, An Anti-Inflammatory Drug With A Novel Mechanism Of Action

Funxional Therapeutics Ltd (Funxional) has announced the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs). The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients. "We are extremely pleased with the outcome of this initial clinical study with FX125L," said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. "The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L." About Funxional Therapeutics Ltd. Funxional Therapeutics is a privately held, clinical stage pharmaceutical company based in Cambridge (UK) which focuses on novel anti-inflammatory therapies. FXT is managed by a very experienced team and is financed by Index Ventures and Novo A/S, while its shareholders also include Ipsen and Cambridge University. FXT has research and office facilities in Cambridge. About BSCIs BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases. BSCIs are one of the three proprietary technology platforms in FXT"s portfolio all of which originated in the University of Cambridge. BSCIs were discovered based upon a strategy that exploits functional screening to develop novel new classes of drugs. FX125L is the lead drug candidate in this novel class, while other BSCIs have been identified as back up molecules or as candidates for development as topical anti-inflammatory agents. Funxional Therapeutics Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009